A detailed history of Larson Financial Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Larson Financial Group LLC holds 194 shares of HALO stock, worth $8,877. This represents 0.0% of its overall portfolio holdings.

Number of Shares
194
Previous 2 9600.0%
Holding current value
$8,877
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$51.3 - $64.42 $9,849 - $12,368
192 Added 9600.0%
194 $11,000
Q4 2023

Feb 01, 2024

BUY
$33.32 - $42.1 $66 - $84
2 New
2 $0

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.37B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.